Jazz Pharmaceuticals plc
JAZZ
$138.81
$2.361.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.12% | 5.23% | 3.91% | 2.81% | 4.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.12% | 5.23% | 3.91% | 2.81% | 4.78% |
| Cost of Revenue | 10.56% | -0.57% | -10.86% | -19.40% | -15.65% |
| Gross Profit | 5.69% | 5.84% | 5.65% | 5.64% | 7.33% |
| SG&A Expenses | 8.31% | 8.48% | 1.32% | 0.05% | -3.99% |
| Depreciation & Amortization | 3.13% | 4.35% | 6.36% | 6.48% | 1.52% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.28% | 6.09% | 6.51% | 6.67% | 5.46% |
| Operating Income | 5.49% | 1.93% | -6.37% | -12.26% | 2.06% |
| Income Before Tax | 58.92% | 470.92% | 209.82% | 171.91% | 177.06% |
| Income Tax Expenses | 23.75% | 64.36% | 45.68% | 46.75% | 24.41% |
| Earnings from Continuing Operations | 35.02% | 479.28% | 556.49% | 311.66% | 285.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.02% | 479.28% | 556.49% | 311.66% | 285.14% |
| EBIT | 5.49% | 1.93% | -6.37% | -12.26% | 2.06% |
| EBITDA | 4.50% | 2.96% | -0.78% | -4.09% | 1.79% |
| EPS Basic | 38.88% | 504.09% | 546.70% | 310.66% | 284.74% |
| Normalized Basic EPS | 19.44% | 14.99% | 1.04% | -15.38% | 10.72% |
| EPS Diluted | 43.64% | 710.31% | 468.70% | 290.43% | 272.08% |
| Normalized Diluted EPS | 30.17% | 16.42% | -2.81% | -20.95% | -1.75% |
| Average Basic Shares Outstanding | -2.29% | -1.67% | -0.87% | 0.18% | 1.21% |
| Average Diluted Shares Outstanding | -10.91% | -5.91% | -0.01% | 5.32% | 14.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
